Kaken Pharmaceutical (TYO:4521) revised its consolidated earnings forecast for the fiscal year ending March 31, raising net sales outlook to 94 billion yen due to an upfront payment from a licensing deal for its STAT6 inhibitor.
Net profit was slightly adjusted downward to 14 billion yen, reflecting expenses from a recent dermatology licensing agreement and the acquisition of Aadi Subsidiaries, according to its Tuesday bourse filing.
The revision follows deals disclosed in December 2024 and March 2025, including a collaboration with Alumis for ESK-001 in Japan and the completion of Aadi's acquisition.
Despite the adjustments, Kaken's projected earnings still show significant growth compared with the previous fiscal year, with net sales up 30.5% and operating profit more than doubling.
Shares of the company dropped over 5% in morning trade Wednesday.
Price (JPY): $4236.00, Change: $-230, Percent Change: -5.13%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。